Venetoclax and Azacitidine for Therapy-Related MDS

Phase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy Related Myelodysplastic Syndrome (t-MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
53 patients (estimated)
Sponsors
Ohio State University Comprehensive Cancer Center
Tags
Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA)
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1481
NCT Identifier
NCT05379166

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.